Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| RAYA | Erayak Power Solution Group | $3.70 | $0.50 | 1351.35% | 1.6K | $3.6M | $3.10$7,370.00 |
| CNSP | Cns Pharmaceuticals | $10.06 | $7.75 | 335.29% | 44.8M | $1.9M | $1.90$34.80 |
| PN | Skycorp Solar Group | $5.36 | $2.49 | 87.08% | 26.9M | $41M | $2.18$87.40 |
| GBTG | Global Business Travel Group | $9.32 | $3.39 | 57.08% | 36.3M | $3.1B | $4.96$9.37 |
| RLYB | Rallybio | $13.81 | $4.40 | 46.76% | 6.5M | $50M | $2.16$14.02 |
| NIVF | NewGenIvf Group | $2.15 | $0.44 | 25.73% | 575.8K | $972K | $1.52$1,839.00 |
| ADVB | Advanced Biomed | $6.41 | $1.14 | 21.63% | 3.6M | $7.2M | $3.61$48.80 |
| CRCG | Themes ETF Trust - Leverage Shares 2x Long Crcl Daily ETF | $3.24 | $0.49 | 17.82% | 9.5M | - | $0.95$20.92 |
| BZAI | Blaize | $2.39 | $0.36 | 17.73% | 6.8M | $249M | $1.00$6.76 |
| ASRT | Assertio | $21.66 | $3.19 | 17.24% | 461K | $119M | $8.61$21.68 |
| SSM | Sono Group | $6.96 | $0.96 | 16.00% | 142.5K | $8.8M | $5.34$27.73 |
| CRE | Cre8 Enterprise | $2.78 | $0.37 | 15.35% | 6.8M | $15M | $1.68$102.18 |
| SNSE | Sensei Biotherapeutics | $31.00 | $4.04 | 14.98% | 8K | $36M | $5.25$36.76 |
| MRDN | Golden Matrix Group | $12.63 | $1.63 | 14.82% | 11.6K | $139M | $5.80$23.76 |
| CLNN | Clene | $7.04 | $0.90 | 14.66% | 14M | $72M | $2.28$13.50 |
| CELC | Celcuity | $143.50 | $17.85 | 14.21% | 45.8K | $6.1B | $9.51$144.21 |
| CABA | Cabaletta Bio | $3.35 | $0.41 | 13.95% | 6.1M | $327M | $1.11$3.78 |
| DARE | Daré Bioscience | $2.65 | $0.31 | 13.46% | 152.9K | $34M | $1.27$9.19 |
| NBIG | Themes ETF Trust - Leverage Shares 2x Long Nbis Daily ETF | $17.03 | $1.92 | 12.71% | 228K | - | $4.51$19.45 |
| NBIL | GraniteShares ETF Trust - GraniteShares 2x Long Nbis Daily ETF | $24.28 | $2.68 | 12.41% | 248.5K | - | $6.37$38.58 |
| HTCO | High-Trend International Group | $8.87 | $0.97 | 12.30% | 260.8K | $58M | $4.55$61.75 |
| FSTR | L.B. Foster Co. | $33.71 | $3.01 | 9.80% | 31.2K | $321M | $17.16$34.46 |
| MUU | Direxion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares | $322.04 | $26.25 | 8.88% | 396.4K | - | $10.28$324.00 |
| MULL | GraniteShares ETF Trust - GraniteShares 2x Long Mu Daily ETF | $282.61 | $22.16 | 8.51% | 50.6K | - | $9.16$284.57 |
| CDIO | Cardio Diagnostics | $2.03 | $0.15 | 7.98% | 26.6K | $5.6M | $0.97$14.46 |
| EEIQ | EpicQuest Education Group International | $3.54 | $0.26 | 7.93% | 9.3K | $4.9M | $1.90$27.84 |
| CUE | Cue Biopharma | $32.76 | $2.34 | 7.69% | 142.4K | $99M | $4.97$38.00 |
| RDAC | Rising Dragon Acquisition Corp. | $10.00 | $0.71 | 7.64% | 22.4K | $55M | $4.59$23.99 |
| IREG | Themes ETF Trust - Leverage Shares 2x Long Iren Daily ETF | $16.96 | $0.96 | 6.01% | 14.8K | - | $7.74$41.60 |
| CRWG | Themes ETF Trust - Leverage Shares 2x Long Crwv Daily ETF | $5.55 | $0.31 | 5.92% | 3.8M | - | $1.80$19.63 |
| TMCR | Metals Royalty | $16.40 | $0.70 | 4.44% | 3.9K | $864M | $5.00$21.38 |
| AURA | Aura Biosciences | $7.32 | $0.31 | 4.42% | 136K | $450M | $4.35$7.68 |
| CGEM | Cullinan Therapeutics | $13.85 | $0.42 | 3.09% | 32.6K | $825M | $5.68$16.74 |
| ESCA | Escalade | $18.75 | $0.54 | 2.94% | 4.6K | $249M | $11.41$19.11 |
| VACH | Voyager Acquisition Corp. | $12.72 | -$0.08 | -0.63% | 43.6 | $402M | $8.81$15.68 |
Related Articles
Featured Article
3 Biotech Start-Ups That Could Soar in 2020
Cory Renauer|Jan 27, 2020
Concept-proving results for lead programs at these biotechs will send their stock prices soaring or sinking before the year's over.
3 Growth Stocks That Could Put Netflix's Returns to Shame
Anders Bylund, Dan Caplinger, and Chuck Saletta|Apr 20, 2018
The streaming video veteran has created a lot of shareholder wealth in recent years. These stocks just might do even better in the future.
Why Avis Budget Group, Depomed, and Tenet Healthcare Slumped Today
Dan Caplinger|Aug 8, 2017
These stocks helped drag the market lower. Find out why.
3 Companies That Need to Kick Their CEO to the Curb
Todd Campbell, Rich Smith, and Tim Brugger|Feb 19, 2017
Here's why Fitbit, Depomed, and Twitter might benefit from a fresh set of eyes in the C-suite.
